40 GUEST STREET, BOSTON, MA
Stockholders Approve 2026 Stock Incentive Plan at Special Meeting
Material disclosure
Reports First Quarter 2026 Financial Results and Recent Strategic Developments
Expands Pipeline with Exclusive License for Clinical-Stage Dual-Mechanism Anti-IgE Antibody
Stockholders Elect Pasha Sarraf to Cue Biopharma Board of Directors
Other Events
Lucinda Warren Appointed Interim CEO; Usman Azam Resigns
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence